title: Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay.
abstract: BACKGROUND
  While the classical NF-κB/p65 pathway is known to be involved in prostate cancer progression and is associated with poor patient outcome, the role of the NF-κB /RelB alternative protein is not well defined. Here we analyzed the activation of both NF-κB pathways in prostate cancer tissues and correlate this activation with clinical features of the disease.
  
  
  METHODS
  A multiple immunofluorescence technique was employed to concomitantly and quantitatively visualize the nuclear localization of p65 and RelB in 200 paraffin embedded samples. Epithelia were defined using appropriate fluorochrome markers and the resulting immunofluorescent signals were quantified with an automated scoring system.
  
  
  RESULTS
  The nuclear frequency of p65 was found to be significantly increased in tumor tissues as compared with normal adjacent tissue, whereas the frequency for RelB was decreased (p < 0.001, Wilcoxon test). As previously reported, p65 nuclear frequency was associated with a risk of biochemical recurrence. Although, RelB nuclear frequency alone did not predict recurrence, the presence of activated RelB reduced the risk of recurrence associated with the activation of p65.
  
  
  CONCLUSIONS
  For the first time p65/RelB co-distribution was assessed in prostate cancer tissues and suggested a negative crosstalk between the two NF-κB pathways in prostate cancer progression.
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Labouba
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada.
authors.forename: Cécile
authors.initials: C
authors.lastname: Le Page
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada.
authors.forename: Laudine
authors.initials: L
authors.lastname: Communal
authors.affiliation: Visiopharm, Argen Allé 3, Hoersholm, Denmark.
authors.forename: Torbjoern
authors.initials: T
authors.lastname: Kristessen
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada.
authors.forename: Xiaotian
authors.initials: X
authors.lastname: You
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Péant
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada.
authors.forename: Véronique
authors.initials: V
authors.lastname: Barrès
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada.
authors.forename: Philippe O
authors.initials: PO
authors.lastname: Gannon
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada; Department of Medicine, Université de Montréal, Montreal, Canada.
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Mes-Masson
authors.affiliation: Institut du cancer de Montréal / Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 900 rue St-Denis, Montreal, Canada; Division of Urology, CHUM and Department of Surgery, Université de Montréal, Montreal, Canada.
authors.forename: Fred
authors.initials: F
authors.lastname: Saad
mesh_terms: D002467:Cell Nucleus / Q000378:metabolism* / Q000648:ultrastructure; D015331:Cohort Studies; D018450:Disease Progression; D005455:Fluorescent Antibody Technique; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008867:Microtomy; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D016612:Paraffin Embedding; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D015398:Signal Transduction; D013194:Staining and Labeling; D046888:Tissue Array Analysis; D051996:Transcription Factor RelA / Q000235:genetics / Q000378:metabolism*; D051841:Transcription Factor RelB / Q000235:genetics / Q000378:metabolism*
chemical_list: C497593:RELB protein, human; D051996:Transcription Factor RelA; D051841:Transcription Factor RelB